Universita' Di Pisa
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
At Universita' Di Pisa, research in congenital and hereditary diseases focuses on children and patients with serious rare conditions, especially high-risk neuroblastoma and primary mitochondrial disease. The trials are designed to test new treatment strategies, refine disease monitoring, and better understand treatment response in complex inherited disorders.
- Evaluating treatment strategies for high-risk neuroblastoma to improve long-term disease control
- Studying primary mitochondrial disease to assess safety, tolerability, and biological response to therapy
- Improving outcomes in rare pediatric and inherited conditions through more effective treatment approaches
This area brings together pediatric oncology and rare disease research, with a strong emphasis on finding better options for patients with limited treatment choices.
Immune System Diseases
Clinical research in immune system diseases at this site includes work on primary Sjogren's syndrome, with studies aimed at identifying better ways to measure response and improve treatment effectiveness. The goal is to support more personalized care for patients living with chronic autoimmune disease.
- Investigating primary Sjogren's syndrome to improve clinical endpoints and assess how well treatments work
- Exploring combinations of existing therapies to strengthen symptom control in autoimmune disease
- Advancing rheumatology research through better evaluation of patient response
The Department of Maternal and Child Health contributes to research that aims to make autoimmune treatment assessment more accurate and clinically meaningful.
Musculoskeletal Diseases
Research in musculoskeletal diseases at Universita' Di Pisa includes studies in primary mitochondrial disease, particularly for patients affected by myopathy and cardiomyopathy. These trials are focused on understanding safety, tolerability, and whether treatment can improve key disease-related symptoms.
- Assessing therapies for myopathy linked to rare metabolic and hereditary disorders
- Monitoring treatment effects in cardiomyopathy associated with mitochondrial disease
- Supporting better management of muscle and movement-related complications in rare disease care
This work connects neuromuscular research with broader efforts to improve quality of life in patients with chronic, disabling conditions.
Neoplasms
The neoplasm research portfolio at this site is centered on prostate cancer and high-risk neuroblastoma. The trials are designed to evaluate treatment effectiveness, track longer-term safety, and test new combinations or strategies for patients with difficult-to-treat cancers.
- Studying prostate cancer to gather long-term safety information after prior treatment
- Testing more effective approaches for high-risk neuroblastoma, including improved disease control after initial therapy
- Exploring oncology strategies that may strengthen response in patients with residual or metastatic disease
Cancer research at Universita' Di Pisa combines pediatric oncology and adult oncology interests, with a focus on improving outcomes in aggressive and advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita' Di Pisa
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa | Swedish Orphan Biovitrum AB (publ) | Phase III | Not Yet Recruiting | Jul 2023 | Dec 2023 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2024-11-21 | 2025-01-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.